Serum Institute of India: News
22 Dec 2022
Drugs Controller General of IndiaSerum Institute seeks DCGI's approval for Covovax as booster dose
The Serum Institute of India (SII) has sought the Drugs Controller General of India's (DCGI) approval to roll out its Covovax in the market as a booster dose for adults.
29 Nov 2022
Gautam AdaniIndia's 100 richest amassed $25bn more wealth in 2022: Forbes
While the rupee has weakened, raising concerns of inflation and looming recession for the rest of the Indians, it has seemingly no effect on the country's richest bunch.
26 Nov 2022
PuneCovishield manufacturer SII duped of Rs. 1 crore, 7 arrested
In a major cheating and cyber fraud case, the Serum Institute of India (SII) has been duped of Rs. 1 crore.
03 Sep 2022
Bombay High CourtCovishield death: Bombay HC notice to Centre, Serum Institute, DCGI
A man has filed a compensation suit against the Indian vaccine maker Serum Institute of India (SII) for Rs. 1,000 crore, claiming that the side effects of the Covishield vaccine killed his daughter last year.
31 Aug 2022
CancerIndia to get its first indigenous cervical cancer vaccine today
India is all set to get its first indigenous cervical cancer vaccine this week.
26 Jul 2022
VaccineIs SII developing vaccine for monkeypox? Here's what Poonawalla said
Amid the rising monkeypox scare, Serum Institute of India (SII) CEO Adar Poonawalla said on Tuesday they are in talks with American biotech company Novavax to develop a messenger RNA (mRNA) vaccine for it.
29 Apr 2022
VaccineIndia inching closer to launching its first dengue vaccine
India is likely to get its first vaccine for dengue soon as the Indian Council of Medical Research (ICMR) is all set to submit its clinical trial protocol to the country's drug regulator CDSCO by June.
09 Apr 2022
COVID-19COVID-19 vaccine precautionary dose service charge capped at Rs. 150
The Centre on Saturday announced that private vaccination centers can charge a service fee of up to Rs. 150 in addition to the cost of the precautionary dose of the COVID-19 vaccine from beneficiaries.
09 Mar 2022
VaccineDCGI approves emergency use of Covovax in children above 12
The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation to the coronavirus vaccine Covovax for restricted emergency use in children above the age of 12.
07 Mar 2022
VaccineGovt panel okays phase-3 trials of Covovax as booster dose
The subject expert committee (SEC) of India's drug regulatory authority Central Drugs Standard Control Organization (CDSCO) has recommended phase-3 clinical trials of Covovax as a booster dose against COVID-19 in adults, Mint reported.
19 Jan 2022
World Health OrganizationOnly faster COVID-19 vaccinations can end pandemic: Adar Poonawalla
Billions need to be vaccinated at a faster rate to reach the end of the COVID-19 pandemic, said Adar Poonawalla, CEO of the Serum Institute of India (SII), which manufactures the COVID-19 vaccine Covishield.
15 Dec 2021
Adar PoonawallaSII to launch COVID-19 vaccine for children in 6 months
The Serum Institute of India is looking to launch a COVID-19 vaccine for children in six months, SII CEO Adar Poonawalla said Tuesday.
03 Dec 2021
PfizerCOVID-19 vaccine: Study finds AstraZeneca booster jab safe, effective
Seven COVID-19 vaccines are safe and stimulate a strong immune response when used as a booster jab to those who have already vaccinated, a study published in The Lancet said.
01 Dec 2021
Zydus CadilaAre Indian vaccines effective against Omicron? Here's what manufacturers say
The COVID-19 vaccine manufacturers in India are reportedly waiting for "more data" on the new coronavirus variant, Omicron, to assess the efficacy of their vaccines.
29 Sep 2021
World Health OrganizationSerum gets nod for Novavax trial in 7-11 age group
The Serum Institute of India (SII) has received the approval to conduct trials of the Novavax COVID-19 vaccine in children aged between seven and 11 years.
14 Aug 2021
CovishieldSII's Poonawalla bats for booster dose, opposes mixing of vaccines
Serum Institute of India Chairman Cyrus Poonawalla on Friday said that taking a third or booster dose of Covishield, the coronavirus vaccine manufactured by his firm was desirable.
17 Jul 2021
EuropeEU body says it didn't receive application for Covishield approval
The European Medicines Agency (EMA) said it has not received any application for the authorization of the coronavirus vaccine Covishield.
13 Jul 2021
CoronavirusCOVID-19: Serum to start producing Sputnik V vaccine from September
The Serum Institute of India (SII) will begin producing the Russian COVID-19 vaccine, Sputnik V, from September, the Russian Direct Investment Fund (RDIF) announced today.
Expert panel says no to Covovax's children trials in India
A Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has denied permission to Pune-based Serum Institute of India (SII) for conducting clinical trials of its second COVID-19 vaccine, Covovax, in children.
'Not received Covishield approval request,' says EU body amid concerns
The Serum Institute of India (SII) has not yet applied for the approval of its coronavirus vaccine Covishield in the "Green Pass" issued by the European Union, according to a statement from the EU.
26 Jun 2021
CoronavirusSerum to begin Covovax trials on children in July
The Serum Institute of India (SII) will soon apply for regulatory approval to conduct clinical trials of Covovax on children in India.
19 Jun 2021
World Health OrganizationEfforts on to restart AstraZeneca shipments from India: WHO official
The WHO is urgently trying to work with AstraZeneca, Serum Institute of India (SII) as well as the Indian government to restart shipments of COVID-19 vaccines to countries, a senior official at the UN health agency said.
17 Jun 2021
VaccineCovovax India launch by September; trial for kids soon: SII
The Serum Institute of India (SII) is looking to launch the COVID-19 vaccine developed by the United States firm Novavax in India by September.
03 Jun 2021
PfizerAfter Pfizer and Moderna, Serum seeks indemnity over COVID-19 vaccine
The Serum Institute of India has requested the Indian government to provide it indemnity from liability in connection with its COVID-19 vaccines, company sources cited by NDTV and The Hindu say.
28 May 2021
Aam Aadmi Party (AAP)Centre creating 'artificial scarcity' of COVID-19 vaccines: AAP
The AAP on Friday alleged that the Centre is creating artificial scarcity of COVID-19 vaccines to benefit Bharat Biotech and Serum Institute of India, a charge termed by the Delhi BJP as unfounded.
13 May 2021
VaccineGovernment panel recommends 12-16 week gap between Covishield doses
A government expert panel has reportedly recommended raising the time gap between two doses of the COVID-19 vaccine Covishield to 12-16 weeks.
13 May 2021
Government of IndiaCoronavirus vaccine production to reach 9cr doses in June: Government
The Serum Institute of India and Bharat Biotech, the two companies India has entrusted to make its coronavirus vaccines, have both submitted their productions plans for the coming four months to the Indian government.
12 May 2021
VaccineUS looking to produce of J&J's COVID-19 vaccine in India
The United States is considering the production of Johnson & Johnson's COVID-19 vaccine in India along with ways to help manufacturers like the Serum Institute of India (SII) to boost production, Daniel B Smith, Charge d'Affaires of the US Embassy, said on Tuesday.
04 May 2021
MaharashtraGive priority to Maharashtra in vaccine allocation: Tope to Poonawalla
Maharashtra Health Minister Rajesh Tope on Monday urged Serum Institute of India Chief Executive Officer Adar Poonawalla to give priority to the state in providing its anti-coronavirus vaccine, Covishield, as the government was ready to purchase doses from the Pune-based company.
03 May 2021
IndiaSII given over Rs. 1,700cr for 11cr Covishield doses: Centre
The Health Ministry on Monday said that a 100 percent advance of Rs. 1732.50 crore was released to the Serum Institute of India on April 28 for 11 crore doses of Covishield vaccine during May, June, and July.
02 May 2021
VaccineGetting aggressive calls from powerful people: SII CEO Adar Poonawalla
Serum Institute of India CEO Adar Poonawalla has revealed that his decision to fly to London when India is facing a COVID-19 second wave was largely due to the threats he had been facing.
28 Apr 2021
VaccineCovishield price reduced to Rs. 300 for states: Adar Poonawalla
Adar Poonawalla, the CEO of the Serum Institute of India (SII), on Wednesday announced that the price of the COVID-19 vaccine Covishield was being reduced from Rs. 400 to Rs. 300 for states.
27 Apr 2021
Government of IndiaCOVID-19: Government asks SII, Bharat Biotech to cut vaccine prices
The central government has asked the Serum Institute of India (SII) and Bharat Biotech to reduce the prices of their COVID-19 vaccines, PTI reported on Monday.
21 Apr 2021
CoronavirusSII fixes Covishield's price at Rs. 600 for private hospitals
Serum Institute of India (SII) will sell Covishield at Rs. 400 per shot to states and at Rs. 600 to private hospitals, the Pune-based vaccine manufacturer said today.
20 Apr 2021
United States of AmericaWe understand India's pharmaceutical requirements: Biden administration
The Biden administration has conveyed to New Delhi that it understands India's pharmaceutical requirements and promised to give the matter due consideration, observing that the current difficulty in the export of critical raw materials needed to manufacture COVID-19 vaccines is mainly due to an Act that forces American companies to prioritize domestic consumption.
09 Apr 2021
South AfricaIndia's Serum Institute refunds South Africa for undelivered coronavirus vaccines
Pune-based Serum Institute of India (SII) has fully refunded South Africa for 500,000 undelivered doses of the coronavirus vaccine, reports PTI.
08 Apr 2021
Adar PoonawallaAstraZeneca serves legal notice to Serum Institute over vaccine delays
Serum Institute of India (SII), the manufacturer of the coronavirus vaccine Covishield, has been served a legal notice by the drug maker AstraZeneca over delays in vaccine supply, the company's CEO Adar Poonawalla confirmed in an interview earlier this week.
06 Apr 2021
VaccineCovishield 90% effective if doses given 2-3 months apart: Poonawalla
The efficacy of the COVID-19 vaccine Covishield could increase to 90% if the two doses are given 2.5-3 months apart, Serum Institute of India CEO Adar Poonawalla said Monday.
27 Mar 2021
Adar PoonawallaSerum CEO Poonawalla hopes to launch second vaccine by September
Serum Institute of India CEO Adar Poonawalla today said that his company hopes to launch its second coronavirus vaccine by September this year.
25 Mar 2021
VaccineAmid growing cases, India temporarily halts export of AstraZeneca's vaccine
Facing a sudden spike in coronavirus cases, India has halted the export of the AstraZeneca vaccine for now, Reuters reported quoting two sources. Millions of doses of the vaccine are being manufactured by the Pune-based Serum Institute of India (SII), the world's biggest vaccine-maker.